ABBOTT PARK, Ill. -- Abbott Laboratories announces that the United States Department of Agriculture (USDA) has given Abbott permission to sell and distribute its bovine spongiform encephalopathy (BSE) test. The rapid Enfer BSE test provides
results within hours, is easy to use and addresses the workflow needs of USDA-
approved screening laboratories. The test detects the presence of the abnormal proteins believed to cause BSE -- commonly known as mad cow disease.
"The Enfer BSE test has been successful in Europe and Japan, where large scale screening is mandatory," said Joseph M. Nemmers, senior vice president of diagnostic operations at Abbott Laboratories. "As a leader in diagnostic testing and blood screening, we will continue to work with the USDA and offer this high-quality test as part of an overall BSE screening solution."
Since entering into a marketing and distribution agreement in 2001 with Ireland-based Enfer Scientific Ltd., Abbott has been selling the test outside the United States and has exclusive rights to sell the test throughout the world except in Ireland. The Enfer BSE test is approved for cattle testing in the European Union and Japan.
"The rapid Enfer BSE assay tests every bovine brain sample in duplicate," said Jim Koziarz, Ph.D., vice president, research and development, diagnostics, Abbott Laboratories. "If either test result is reactive, the brain specimen is resampled and retested in duplicate. This type of testing method ensures that a true positive would be reliably detected."
More than 3 million samples have been tested for transmissible spongiform encephalopathies (TSEs) using the Enfer test. Additionally, Enfer Scientific is the world's largest TSE screening laboratory routinely performing up to 9,000 tests per day and providing results to beef processors within a minimum turnaround time of 12 hours.
Prior to the approval of rapid BSE tests, the USDA used an immunohistochemistry BSE test which took several days to perform and report the results.
Abbott Laboratories is a global, broad-based healthcare company devoted to the discovery, development, manufacture and marketing of pharmaceutical and medical products, including nutritionals, devices and diagnostics. The company employs more than 70,000 people and markets its products in more than 130 countries.
Source: Abbott Laboratories
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.